{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:48:18Z","timestamp":1791874098780,"version":"4.3.4"},"reference-count":215,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) is a rare autoimmune disorder caused by autoantibodies targeting postsynaptic proteins of the neuromuscular junction. Although conventional therapies can achieve remission or sufficient symptom control in most patients with generalized MG (gMG), approximately 10%\u201330% of patients remain treatment refractory with an increased risk of myasthenic crises and mortality. In addition, prolonged immunosuppression can cause undesirable side effects. Over the past decade, research has focused on identifying new therapeutic targets, which paved the way to advance the development of novel therapies. Rather than exerting broad immunosuppression, novel therapies selectively target specific components involved in the immunopathogenesis of MG, such as immunoglobulin G (IgG) production (B cell\u2010depleting agents), IgG recycling (neonatal fragment crystallizable receptor, FcRn, blocker), and complement activation (complement inhibitors). Targeted therapies have been evolving exponentially since 2017, marking a new era in treatment strategies in gMG. They have emerged as potential steroid\u2010sparing agents with robust efficacy and favorable safety profiles. Small cohorts have demonstrated the efficacy and tolerability of these therapies during myasthenic crisis and in patients with active thymoma. Although targeted therapies have generally comparable efficacy and safety, treatment plans should be individualized, and several factors should be considered before initiating these therapies, including pharmacological spectrum (complement inhibitors are effective only in acetylcholine receptor antibody\u2010positive MG, while FcRn and B cell\u2010depleting agents have broader spectra), convenience of administration, and cost\u2010effectiveness. This monograph proposes an updated treatment algorithm in refractory gMG that integrates novel targeted therapies alongside standard immunosuppressant steroid\u2010sparing agents.<\/jats:p>","DOI":"10.1002\/mus.70418","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:06:01Z","timestamp":1791871561000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Expanding Therapeutic Landscape in Myasthenia Gravis"],"prefix":"10.1002","author":[{"given":"Hebatallah R.","family":"Rashed","sequence":"first","affiliation":[{"name":"Department of Neurology Ain Shams University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"4","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical Evaluation and Management of Myasthenia Gravis","volume":"29","author":"Keesey J. C.","year":"2004","journal-title":"Muscle & Nerve"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864261429176","article-title":"A Delphi Consensus on Integrating Novel Therapies Into the Management of Generalized Myasthenia Gravis","volume":"19","author":"Vissing J.","year":"2026","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"2","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime Course of Myasthenia Gravis","volume":"37","author":"Grob D.","year":"2008","journal-title":"Muscle & Nerve"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","DOI":"10.1186\/s42466-019-0023-3","article-title":"SOP Myasthenic Crisis","volume":"1","author":"Stetefeld H.","year":"2019","journal-title":"Neurology Research and Practice"},{"issue":"7","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070671","article-title":"Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture","volume":"8","author":"Koneczny I.","year":"2019","journal-title":"Cells"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK\u2010Positive Myasthenia Gravis; an IgG4 Antibody\u2010Mediated Disease","volume":"14","author":"Vakrakou A. G.","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody Specificities in Myasthenia Gravis: Implications for Improved Diagnostics and Therapeutics","volume":"11","author":"Lazaridis K.","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/brainsci13091286","article-title":"Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows","volume":"13","author":"Vinciguerra C.","year":"2023","journal-title":"Brain Sciences"},{"issue":"9","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical Value of Cell\u2010Based Assays in the Characterisation of Seronegative Myasthenia Gravis","volume":"93","author":"Damato V.","year":"2022","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4\u2010IgG Service Line Testing in Seronegative Myasthenia Gravis and Controls","volume":"368","author":"Klein C. J.","year":"2022","journal-title":"Journal of Neuroimmunology"},{"issue":"10","key":"e_1_2_12_12_1","first-page":"1296.e84","article-title":"Clinical Analysis of Chinese Anti\u2010Low\u2010Density\u2010Lipoprotein\u2010Receptor\u2010Associated Protein 4 Antibodies in Patients With Myasthenia Gravis","volume":"26","author":"Li M.","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"3","key":"e_1_2_12_13_1","article-title":"Low Prevalence and Inconsistency of LRP4\u2010IgG Detection in Suspected Myasthenia Gravis: A Multicenter CBA Comparison","volume":"13","author":"Gligora I.","year":"2026","journal-title":"Neurology: Neuroimmunology & Neuroinflammation"},{"issue":"6","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/mus.70219","article-title":"Old Foundations in a New Era of Myasthenia Gravis Therapy","volume":"73","author":"Stavros K.","year":"2026","journal-title":"Muscle & Nerve"},{"issue":"1","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia Gravis: Recommendations for Clinical Research Standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki A.","year":"2000","journal-title":"Annals of Thoracic Surgery"},{"issue":"4","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary","volume":"87","author":"Sanders D. B.","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami P.","year":"2021","journal-title":"Neurology"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN Receptor Antagonists in the Management of Myasthenia Gravis","volume":"14","author":"Bhandari V.","year":"2023","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current Treatment of Myasthenia Gravis","volume":"11","author":"Alhaidar M. K.","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"3","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JND-170294","article-title":"New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis","volume":"5","author":"Behin A.","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"10","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies","volume":"14","author":"Gilhus N. E.","year":"2015","journal-title":"Lancet Neurology"},{"issue":"4","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment\u2010Refractory Myasthenia Gravis","volume":"15","author":"Silvestri N. J.","year":"2014","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the Burden of Refractory Myasthenia Gravis","volume":"12","author":"Schneider\u2010Gold C.","year":"2019","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"2","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in Myasthenia Gravis in the Era of Biologics","volume":"15","author":"Dalakas M. C.","year":"2019","journal-title":"Nature Reviews. Neurology"},{"issue":"7","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, Efficacy, and Tolerability of Efgartigimod in Patients With Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo\u2010Controlled, Phase 3 Trial","volume":"20","author":"Howard J. F.","year":"2021","journal-title":"Lancet Neurology"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When Myasthenia Gravis Is Deemed Refractory: Clinical Signposts and Treatment Strategies","volume":"11","author":"Mantegazza R.","year":"2018","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00981","article-title":"From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research","volume":"11","author":"Mantegazza R.","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00604","article-title":"A Practical Approach to Managing Patients With Myasthenia Gravis\u2014Opinions and a Review of the Literature","volume":"11","author":"Farrugia M. E.","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"12","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti\u2010Acetylcholine Receptor Antibody\u2010Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double\u2010Blind, Placebo\u2010Controlled, Multicentre Study","volume":"16","author":"Howard J. F.","year":"2017","journal-title":"Lancet Neurology"},{"issue":"6","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/acn3.70051","article-title":"ADAPT NXT: Fixed Cycles or Every\u2010Other\u2010Week IV Efgartigimod in Generalized Myasthenia Gravis","volume":"12","author":"Habib A. A.","year":"2025","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"5","key":"e_1_2_12_31_1","article-title":"Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis","volume":"1","author":"Vu T.","year":"2022","journal-title":"NEJM Evidence"},{"issue":"6","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs Eculizumab in Adult Patients With PNH Naive to Complement Inhibitors: The 301 Study","volume":"133","author":"Lee J. W.","year":"2019","journal-title":"Blood"},{"issue":"6","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The Long\u2010Acting C5 Inhibitor, Ravulizumab, Is Effective and Safe in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Treatment","volume":"97","author":"Rondeau E.","year":"2020","journal-title":"Kidney International"},{"issue":"5","key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and Efficacy of Zilucoplan in Patients With Generalised Myasthenia Gravis (RAISE): A Randomised, Double\u2010Blind, Placebo\u2010Controlled, Phase 3 Study","volume":"22","author":"Howard J. F.","year":"2023","journal-title":"Lancet Neurology"},{"issue":"5","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and Efficacy of Rozanolixizumab in Patients With Generalised Myasthenia Gravis (MycarinG): A Randomised, Double\u2010Blind, Placebo\u2010Controlled, Adaptive Phase 3 Study","volume":"22","author":"Bril V.","year":"2023","journal-title":"Lancet Neurology"},{"issue":"2","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and Efficacy of Nipocalimab in Adults With Generalised Myasthenia Gravis (Vivacity\u2010MG3): A Phase 3, Randomised, Double\u2010Blind, Placebo\u2010Controlled Study","volume":"24","author":"Antozzi C.","year":"2025","journal-title":"Lancet Neurology"},{"issue":"23","key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis","volume":"392","author":"Nowak R. J.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional Defect in Regulatory T Cells in Myasthenia Gravis","volume":"1274","author":"Thiruppathi M.","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/nyas.13560","article-title":"Pathophysiological Mechanisms of Autoimmunity","volume":"1413","author":"Sudres M.","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms Underlying B Cell Immune Dysregulation and Autoantibody Production in MuSK Myasthenia Gravis","volume":"1412","author":"Stathopoulos P.","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"e_1_2_12_41_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001116","article-title":"IgG4\u2010Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long\u2010Lasting Benefits of Anti\u2010B Cell Therapies","volume":"9","author":"Dalakas M. C.","year":"2022","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"2","key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B Cells in the Pathophysiology of Myasthenia Gravis","volume":"57","author":"Yi J. S.","year":"2018","journal-title":"Muscle & Nerve"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B Cells and Plasma Cells in Autoimmune Diseases","volume":"9","author":"Hofmann K.","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of Anti\u2010B Cell Therapeutics in Autoimmune Neurological Diseases","volume":"19","author":"Stathopoulos P.","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"6","key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s00415-024-12288-2","article-title":"Correction to: Update on the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD)\u2014Revised Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack Therapy and Long\u2010Term Management","volume":"271","author":"Kumpfel T.","year":"2024","journal-title":"Journal of Neurology"},{"issue":"12","key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: First Approval","volume":"80","author":"Frampton J. E.","year":"2020","journal-title":"Drugs"},{"issue":"7","key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for Myasthenia Gravis Developing After Bone Marrow Transplant","volume":"55","author":"Zaja F.","year":"2000","journal-title":"Neurology"},{"issue":"10","key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B Cells as Therapeutic Targets in Autoimmune Neurological Disorders","volume":"4","author":"Dalakas M. C.","year":"2008","journal-title":"Nature Clinical Practice. Neurology"},{"issue":"1","key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B\u2010Cell Subpopulations in Humans and Their Differential Susceptibility to Depletion With Anti\u2010CD20 Monoclonal Antibodies","volume":"15","author":"Leandro M. J.","year":"2013","journal-title":"Arthritis Research & Therapy"},{"issue":"7","key":"e_1_2_12_50_1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.18553\/jmcp.2020.26.7.832","article-title":"Indications for Rituximab Use in an Integrated Health Care Delivery System","volume":"26","author":"Delate T.","year":"2020","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"4","key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody\u2010Positive Generalized Myasthenia Gravis: The BeatMG Study","volume":"98","author":"Nowak R. J.","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"e_1_2_12_52_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001130","article-title":"Exploring Rituximab for the Treatment of Refractory Myasthenia Gravis: A Single\u2010Centre Experience","volume":"7","author":"Roddate M.","year":"2025","journal-title":"BMJ Neurology Open"},{"key":"e_1_2_12_53_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","article-title":"Cladribine Induces Long Lasting Oligoclonal Bands Disappearance in Relapsing Multiple Sclerosis Patients: 10\u2010Year Observational Study","volume":"27","author":"Rejdak K.","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"7","key":"e_1_2_12_54_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208638","article-title":"Oral Cladribine Capsules for Generalized Myasthenia Gravis: Design of the Actively Recruiting Phase 3 MyClad Study (P1\u201011.013)","volume":"104","author":"Rejdak K.","year":"2025","journal-title":"Neurology"},{"issue":"8","key":"e_1_2_12_55_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16322","article-title":"A Multicenter, Randomized, Open\u2010Label, Phase 2 Clinical Study of Telitacicept in Adult Patients With Generalized Myasthenia Gravis","volume":"31","author":"Yin J.","year":"2024","journal-title":"European Journal of Neurology"},{"issue":"11","key":"e_1_2_12_56_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000216993","article-title":"A Phase Three, Randomized, Double\u2010Blind, Placebo\u2010Controlled Study With an Open\u2010Label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (RemeMG) (P9\u20109.005)","volume":"106","author":"Li G.","year":"2026","journal-title":"Neurology"},{"issue":"2","key":"e_1_2_12_57_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","article-title":"Safety and Efficacy of Satralizumab in Patients With Generalised Myasthenia Gravis (LUMINESCE): A Randomised, Double\u2010Blind, Multicentre, Placebo\u2010Controlled Phase 3 Trial","volume":"24","author":"Habib A. A.","year":"2025","journal-title":"Lancet Neurology"},{"key":"e_1_2_12_58_1","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.2147\/JIR.S423098","article-title":"A Pilot Study on Tocilizumab in Very\u2010Late\u2013Onset Myasthenia Gravis","volume":"16","author":"Yang T. T.","year":"2023","journal-title":"Journal of Inflammation Research"},{"issue":"2","key":"e_1_2_12_59_1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.14336\/AD.2023.0528","article-title":"Responsiveness to Tocilizumab in Anti\u2010Acetylcholine Receptor\u2013Positive Generalized Myasthenia Gravis","volume":"15","author":"Jia D.","year":"2024","journal-title":"Aging and Disease"},{"issue":"6","key":"e_1_2_12_60_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial Effect of Tocilizumab in Myasthenia Gravis Refractory to Rituximab","volume":"27","author":"Jonsson D. I.","year":"2017","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"e_1_2_12_61_1","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14793","article-title":"Efficacy and Safety of Tocilizumab in Patients With Refractory Generalized Myasthenia Gravis","volume":"30","author":"Ruan Z.","year":"2024","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"e_1_2_12_62_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1642938","article-title":"Safety Profile and Efficacy of Secukinumab in the Treatment of Autoimmune Myasthenia Gravis: A Single\u2010Center Retrospective Study","volume":"16","author":"Zhang S.","year":"2025","journal-title":"Frontiers in Neurology"},{"issue":"3","key":"e_1_2_12_63_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JND-170211","article-title":"Obinutuzumab Plus Chlorambucil in a Patient With Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia","volume":"4","author":"Russell A.","year":"2017","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"6","key":"e_1_2_12_64_1","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/mus.26707","article-title":"Refractory Myasthenia Gravis Successfully Treated With Ofatumumab","volume":"60","author":"Waters M. J.","year":"2019","journal-title":"Muscle & Nerve"},{"issue":"6","key":"e_1_2_12_65_1","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for Treatment\u2010Refractory Antibody\u2010Mediated Diseases in Neurology","volume":"29","author":"Scheibe F.","year":"2022","journal-title":"European Journal of Neurology"},{"issue":"10","key":"e_1_2_12_66_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in Severe MuSK\u2010Antibody Positive Myasthenia Gravis: First Clinical Experience","volume":"10","author":"Schneider\u2010Gold C.","year":"2017","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"e_1_2_12_67_1","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/mus.25458","article-title":"Remission of Myasthenia Gravis With MuSK Antibodies During Ruxolitinib Treatment","volume":"55","author":"Alboini P. E.","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"1","key":"e_1_2_12_68_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00831","article-title":"Targeting Pathogenic Th17.1 Cells via JAK\u2010STAT3 Pathway: A Novel Approach With Tofacitinib for Refractory Myasthenia Gravis","volume":"23","author":"Zhao R.","year":"2026","journal-title":"Neurotherapeutics"},{"key":"e_1_2_12_69_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.nmd.2024.06.006","article-title":"Baricitinib as a Treatment for Myasthenia Gravis: A Case Report","volume":"41","author":"Iguchi M.","year":"2024","journal-title":"Neuromuscular Disorders"},{"issue":"9","key":"e_1_2_12_70_1","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.ymthe.2025.06.042","article-title":"CD19xCD3 T Cell Engager Blinatumomab Effective in Refractory Generalized Myasthenic Syndromes","volume":"33","author":"Ruck T.","year":"2025","journal-title":"Molecular Therapy"},{"issue":"1","key":"e_1_2_12_71_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti\u2010BCMA CAR T\u2010Cell Therapy CT103A in Relapsed or Refractory AQP4\u2010IgG Seropositive Neuromyelitis Optica Spectrum Disorders: Phase 1 Trial Interim Results","volume":"8","author":"Qin C.","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"11","key":"e_1_2_12_72_1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric Antigen Receptor T Cell Therapy for Autoimmune Disease","volume":"24","author":"Chung J. B.","year":"2024","journal-title":"Nature Reviews. Immunology"},{"issue":"6","key":"e_1_2_12_73_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B Cell\u2010Targeting Chimeric Antigen Receptor T Cells as an Emerging Therapy in Neuroimmunological Diseases","volume":"23","author":"Haghikia A.","year":"2024","journal-title":"Lancet Neurology"},{"issue":"11","key":"e_1_2_12_74_1","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/acn3.70167","article-title":"Durability of Response to B\u2010Cell Maturation Antigen\u2010Directed mRNA Cell Therapy in Myasthenia Gravis","volume":"12","author":"Chahin N.","year":"2025","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"13","key":"e_1_2_12_75_1","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2024015346","article-title":"Immunological Consequences of CAR T\u2010Cell Therapy: An Analysis of Infectious Complications and Immune Reconstitution","volume":"9","author":"Riedel A.","year":"2025","journal-title":"Blood Advances"},{"issue":"1","key":"e_1_2_12_76_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious Complications of CD19\u2010Targeted Chimeric Antigen Receptor\u2010Modified T\u2010Cell Immunotherapy","volume":"131","author":"Hill J. A.","year":"2018","journal-title":"Blood"},{"issue":"12","key":"e_1_2_12_77_1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti\u2010CD19 CAR T Cells for Refractory Myasthenia Gravis","volume":"22","author":"Haghikia A.","year":"2023","journal-title":"Lancet Neurology"},{"issue":"11","key":"e_1_2_12_78_1","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of Concomitant Myasthenia Gravis and Lambert\u2013Eaton Myasthenic Syndrome With Autologous CD19\u2010Targeted CAR T Cells","volume":"112","author":"Motte J.","year":"2024","journal-title":"Neuron"},{"issue":"7","key":"e_1_2_12_79_1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and Clinical Activity of Autologous RNA Chimeric Antigen Receptor T\u2010Cell Therapy in Myasthenia Gravis (MG\u2010001): A Prospective, Multicentre, Open\u2010Label, Non\u2010Randomised Phase 1b\/2a Study","volume":"22","author":"Granit V.","year":"2023","journal-title":"Lancet Neurology"},{"issue":"3","key":"e_1_2_12_80_1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41591-025-04170-z","article-title":"BCMA\u2010Directed mRNA CAR\u2010T Cell Therapy for Myasthenia Gravis: Exploratory Biomarker Analysis of a Placebo\u2010Controlled Phase 2b Trial","volume":"32","author":"Fedak R. R.","year":"2026","journal-title":"Nature Medicine"},{"issue":"1","key":"e_1_2_12_81_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aeb6424","article-title":"BCMA\/CD19 CAR T Cell Therapy for Refractory Myasthenia Gravis: Proteomic Signatures and Single\u2010Cell Transcriptomics of Disease Flares","volume":"12","author":"Huang X.","year":"2026","journal-title":"Science Advances"},{"key":"e_1_2_12_82_1","unstructured":"D. C.Richman \u201cOpen\u2010Label Study to Evaluate the Safety of Various Dosing Regimens of MuSK\u2010CAART for MuSK Myasthenia Gravis \u201d(2022) https:\/\/studypages.com\/s\/open\u2010label\u2010study\u2010to\u2010evaluate\u2010the\u2010safety\u2010of\u2010various\u2010dosing\u2010regimens\u2010of\u2010musk\u2010caart\u2010for\u2010musk\u2010myasthenia\u2010gravis\u2010138941\/."},{"issue":"6","key":"e_1_2_12_83_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long\u2010Term Outcomes Following CAR T Cell Therapy: What We Know So Far","volume":"20","author":"Cappell K. M.","year":"2023","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"2","key":"e_1_2_12_84_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy","volume":"22","author":"Morris E. C.","year":"2022","journal-title":"Nature Reviews. Immunology"},{"issue":"7","key":"e_1_2_12_85_1","first-page":"1111","article-title":"Generation and Characterization of a High Affinity Anti\u2010Human FcRn Antibody, Rozanolixizumab, and the Effects of Different Molecular Formats on the Reduction of Plasma IgG Concentration","volume":"10","author":"Smith B.","year":"2018","journal-title":"MAbs"},{"issue":"12","key":"e_1_2_12_86_1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14712598.2023.2296126","article-title":"An Evaluation of Rozanolixizumab\u2010Noli for the Treatment of Anti\u2010AChR and Anti\u2010MuSK Antibody\u2010Positive Generalized Myasthenia Gravis","volume":"23","author":"Matic A.","year":"2023","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"10","key":"e_1_2_12_87_1","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc Receptor Antagonist Efgartigimod Safely and Sustainably Reduces IgGs in Humans","volume":"128","author":"Ulrichts P.","year":"2018","journal-title":"Journal of Clinical Investigation"},{"issue":"8","key":"e_1_2_12_88_1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn Antagonism on Protective Antibodies and to Vaccines in IgG\u2010Mediated Autoimmune Diseases Pemphigus and Generalised Myasthenia Gravis","volume":"55","author":"Guptill J. T.","year":"2022","journal-title":"Autoimmunity"},{"issue":"2","key":"e_1_2_12_89_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity\u2010MG Study","volume":"102","author":"Antozzi C.","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"e_1_2_12_90_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/1750743X.2025.2491295","article-title":"Rozanolixizumab for Myasthenia Gravis: A Breakthrough Treatment and Future Prospects","volume":"17","author":"Matic A.","year":"2025","journal-title":"Immunotherapy"},{"issue":"23","key":"e_1_2_12_91_1","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis","volume":"92","author":"Howard J. F.","year":"2019","journal-title":"Neurology"},{"issue":"414","key":"e_1_2_12_92_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn Inhibitor Rozanolixizumab Reduces Human Serum IgG Concentration: A Randomized Phase 1 Study","volume":"9","author":"Kiessling P.","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"6","key":"e_1_2_12_93_1","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial","volume":"96","author":"Bril V.","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"e_1_2_12_94_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti\u2010FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First\u2010In\u2010Human Study","volume":"105","author":"Ling L. E.","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"7","key":"e_1_2_12_95_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of Therapeutic Plasma Exchange on Immunoglobulins in Myasthenia Gravis","volume":"49","author":"Guptill J. T.","year":"2016","journal-title":"Autoimmunity"},{"issue":"12","key":"e_1_2_12_96_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in Humans Reduces Circulating IgG Levels and Inhibits IgG Immune Complex\u2010Mediated Immune Responses","volume":"5","author":"Blumberg L. J.","year":"2019","journal-title":"Science Advances"},{"issue":"5","key":"e_1_2_12_97_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous Efgartigimod PH20 in Generalized Myasthenia Gravis: A Phase 3 Randomized Noninferiority Study (ADAPT\u2010SC) and Interim Analyses of a Long\u2010Term Open\u2010Label Extension Study (ADAPT\u2010SC+)","volume":"21","author":"Howard J. F.","year":"2024","journal-title":"Neurotherapeutics"},{"key":"e_1_2_12_98_1","unstructured":"Muscular Dystrophy Association \u201cFDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living With Generalized Myasthenia Gravis \u201d[Press Release] (2026) https:\/\/www.mda.org\/press\u2010releases\/fda\u2010expands\u2010approval\u2010of\u2010vyvgart\u2010and\u2010vyvgart\u2010hytrulo\u2010to\u2010all\u2010adults\u2010living\u2010with\u2010generalized\u2010myasthenia."},{"issue":"7","key":"e_1_2_12_99_1","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1212\/WNL.0000000000210564","article-title":"Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti\u2010Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis (P7\u201011.032)","volume":"104","author":"Howard J. F.","year":"2025","journal-title":"Neurology"},{"issue":"23","key":"e_1_2_12_100_1","first-page":"S41","article-title":"Vibrance\u2010Mg: Clinical Trial of Nipocalimab in Pediatric Myasthenia Gravis","volume":"99","author":"Ramchandren S.","year":"2022","journal-title":"Neurology"},{"key":"e_1_2_12_101_1","unstructured":"J.Johnson \u201cNipocalimab Demonstrates Sustained Disease Control in Adolescents Living With Generalized Myasthenia Gravis in Phase 2\/3 Study \u201d[Press Release] (2024) https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/nipocalimab\u2010demonstrates\u2010sustained\u2010disease\u2010control\u2010in\u2010adolescents\u2010living\u2010with\u2010generalized\u2010myasthenia\u2010gravis\u2010in\u2010phase\u20102\u20103\u2010study."},{"key":"e_1_2_12_102_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel Treatments in Myasthenia Gravis","volume":"11","author":"Menon D.","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"4","key":"e_1_2_12_103_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial","volume":"81","author":"Yan C.","year":"2024","journal-title":"JAMA Neurology"},{"issue":"2","key":"e_1_2_12_104_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic Effects of Batoclimab in Chinese Patients With Generalized Myasthenia Gravis: A Double\u2010Blinded, Randomized, Placebo\u2010Controlled Phase Ii Study","volume":"11","author":"Yan C.","year":"2022","journal-title":"Neurology and Therapy"},{"issue":"5","key":"e_1_2_12_105_1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/cts.13019","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HBM9161, a Novel FcRn Inhibitor, in a Phase I Study for Healthy Chinese Volunteers","volume":"14","author":"Yap D. Y. H.","year":"2021","journal-title":"Clinical and Translational Science"},{"issue":"15","key":"e_1_2_12_106_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","article-title":"RVT\u20101401, a Novel Anti\u2010FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2\u2010079)","volume":"92","author":"Collins J.","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_12_107_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/acn3.51946","article-title":"Subcutaneous Batoclimab in Generalized Myasthenia Gravis: Results From a Phase 2a Trial With an Open\u2010Label Extension","volume":"11","author":"Nowak R. J.","year":"2024","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"1","key":"e_1_2_12_108_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000536","article-title":"Batoclimab as Induction and Maintenance Therapy in Patients With Myasthenia Gravis: Rationale and Study Design of a Phase 3 Clinical Trial","volume":"6","author":"Benatar M.","year":"2024","journal-title":"BMJ Neurol Open"},{"issue":"7","key":"e_1_2_12_109_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of Complement, Anti\u2010Complement Therapeutics, and Other Targeted Immunotherapies in Myasthenia Gravis","volume":"18","author":"Dalakas M. C.","year":"2022","journal-title":"Expert Review of Clinical Immunology"},{"issue":"10","key":"e_1_2_12_110_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement Regulators and Inhibitory Proteins","volume":"9","author":"Zipfel P. F.","year":"2009","journal-title":"Nature Reviews. Immunology"},{"issue":"14","key":"e_1_2_12_111_1","first-page":"1058","article-title":"Complement. First of Two Parts","volume":"344","author":"Walport M. J.","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"e_1_2_12_112_1","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 Antibodies to Acetylcholine Receptors in \u2018Seronegative\u2019 Myasthenia Gravis","volume":"131","author":"Leite M. I.","year":"2008","journal-title":"Brain"},{"issue":"6","key":"e_1_2_12_113_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement Deposition at the Neuromuscular Junction in Seronegative Myasthenia Gravis","volume":"139","author":"Hoffmann S.","year":"2020","journal-title":"Acta Neuropathologica"},{"issue":"1","key":"e_1_2_12_114_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia Gravis: The Role of Complement at the Neuromuscular Junction","volume":"1412","author":"Howard J. F.","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"key":"e_1_2_12_115_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2026.106322","article-title":"Complement C3 Inhibition Restores Myasthenia Gravis AChR Antibody\u2010Mediated Muscle Pathophysiology","volume":"129","author":"Huang Y. F.","year":"2026","journal-title":"eBioMedicine"},{"key":"e_1_2_12_116_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel Immunotherapies for Myasthenia Gravis","volume":"12","author":"Nair S. S.","year":"2023","journal-title":"ImmunoTargets and Therapy"},{"issue":"3","key":"e_1_2_12_117_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The Quantitative Role of Alternative Pathway Amplification in Classical Pathway Induced Terminal Complement Activation","volume":"138","author":"Harboe M.","year":"2004","journal-title":"Clinical and Experimental Immunology"},{"issue":"7","key":"e_1_2_12_118_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000211246","article-title":"Efficacy and Safety of Iptacopan in Patients With Generalized Myasthenia Gravis: Study Design (P7\u201011.027)","volume":"104","author":"Muppidi S.","year":"2025","journal-title":"Neurology"},{"issue":"11","key":"e_1_2_12_119_1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and Development of the Complement Inhibitor Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"25","author":"Rother R. P.","year":"2007","journal-title":"Nature Biotechnology"},{"issue":"6","key":"e_1_2_12_120_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40272-024-00649-3","article-title":"Targeted Treatments for Myasthenia Gravis in Children and Adolescents","volume":"26","author":"Ramdas S.","year":"2024","journal-title":"Paediatric Drugs"},{"issue":"12","key":"e_1_2_12_121_1","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","article-title":"Risk\u2013Benefit Analysis of Novel Treatments for Patients With Generalized Myasthenia Gravis","volume":"41","author":"Smith A. G.","year":"2024","journal-title":"Advances in Therapy"},{"issue":"4","key":"e_1_2_12_122_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and Preclinical Characterization of ALXN1210: A Novel Anti\u2010C5 Antibody With Extended Duration of Action","volume":"13","author":"Sheridan D.","year":"2018","journal-title":"PLoS One"},{"key":"e_1_2_12_123_1","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2147\/NDT.S374694","article-title":"Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence","volume":"19","author":"Vu T.","year":"2023","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"10","key":"e_1_2_12_124_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/cells14100739","article-title":"The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis","volume":"14","author":"Martinez Salazar A.","year":"2025","journal-title":"Cells"},{"issue":"7","key":"e_1_2_12_125_1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic Variants in C5 and Poor Response to Eculizumab","volume":"370","author":"Nishimura J.","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_126_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251347283","article-title":"Switching to Subcutaneous Zilucoplan From Intravenous Complement Component 5 Inhibitors in Generalised Myasthenia Gravis: A Phase IIIb, Open\u2010Label Study","volume":"18","author":"Freimer M.","year":"2025","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"e_1_2_12_127_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2026.106386","article-title":"Zilucoplan Is Effective for Ravulizumab\u2010Refractory Generalized Myasthenia Gravis With the C5 p.Arg885His Variant: A Case Report","volume":"61","author":"Itagaki Y.","year":"2026","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"e_1_2_12_128_1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody\u2010Positive Generalized Myasthenia Gravis","volume":"30","author":"Howard J. F.","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"e_1_2_12_129_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2026.578944","article-title":"Combined Inhibition of Complement C5 and Neonatal Fc Receptor in Refractory Generalized Myasthenia Gravis: A Report of Two Cases","volume":"417","author":"Irie K. I.","year":"2026","journal-title":"Journal of Neuroimmunology"},{"key":"e_1_2_12_130_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.molimm.2023.12.004","article-title":"Characterization of the Bispecific VHH Antibody Gefurulimab (ALXN1720) Targeting Complement Component 5, and Designed for Low Volume Subcutaneous Administration","volume":"165","author":"Jindal S.","year":"2024","journal-title":"Molecular Immunology"},{"issue":"7","key":"e_1_2_12_131_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208763","article-title":"The Phase 3 PREVAIL Study Assessing the Efficacy and Safety of Subcutaneous Gefurulimab in Adults With Generalized Myasthenia Gravis: Trial in Progress (P7\u201011.021)","volume":"104","author":"Howard J.","year":"2025","journal-title":"Neurology"},{"issue":"10540","key":"e_1_2_12_132_1","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(26)00690-2","article-title":"Efficacy and Safety of Cemdisiran siRNA in Myasthenia Gravis (NIMBLE): A Double\u2010Blind, Randomised, Placebo\u2010Controlled, Phase 3 Trial","volume":"407","author":"Vu T.","year":"2026","journal-title":"Lancet"},{"issue":"27","key":"e_1_2_12_133_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/pai.13635","article-title":"Inherited Defects in the Complement System","volume":"33","author":"Leonardi L.","year":"2022","journal-title":"Pediatric Allergy and Immunology"},{"key":"e_1_2_12_134_1","unstructured":"Centers for Disease Control and Prevention \u201cClinical Guidance for Managing Meningococcal Disease Risk in Patients Receiving Complement Inhibitor Therapy \u201d(2026) https:\/\/www.cdc.gov\/meningococcal\/hcp\/clinical\u2010guidance\/complement\u2010inhibitor.html."},{"issue":"4","key":"e_1_2_12_135_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections Associated With the Use of Eculizumab: Recommendations for Prevention and Prophylaxis","volume":"29","author":"Benamu E.","year":"2016","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"7","key":"e_1_2_12_136_1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for Treatment of Autoimmune Neuromuscular Transmission Disorders","volume":"17","author":"Skeie G. O.","year":"2010","journal-title":"European Journal of Neurology"},{"issue":"3","key":"e_1_2_12_137_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","article-title":"A Comparison of the Effectiveness of Intravenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia Gravis","volume":"9","author":"Jensen P.","year":"2008","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"1","key":"e_1_2_12_138_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti\u2010MuSK Antibody Myasthenia Gravis: Clinical Findings and Response to Treatment in Two Large Cohorts","volume":"44","author":"Guptill J. T.","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"1","key":"e_1_2_12_139_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1537-2995.1982.22182154218.x","article-title":"Changes in Coagulation Factors, Complement, Immunoglobulins, and Immune Complex Concentrations With Plasma Exchange","volume":"22","author":"Volkin R. L.","year":"1982","journal-title":"Transfusion"},{"issue":"2","key":"e_1_2_12_140_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1529-8027.2010.00263.x","article-title":"Long\u2010Term Regular Plasmapheresis as a Maintenance Treatment for Chronic Inflammatory Demyelinating Polyneuropathy","volume":"15","author":"Isose S.","year":"2010","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"4","key":"e_1_2_12_141_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/mus.27922","article-title":"Updated Consensus Statement: Intravenous Immunoglobulin in the Treatment of Neuromuscular Disorders Report of the AANEM ad Hoc Committee","volume":"68","author":"Tavee J.","year":"2023","journal-title":"Muscle & Nerve"},{"issue":"23","key":"e_1_2_12_142_1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in Patients With Myasthenia Gravis","volume":"76","author":"Barth D.","year":"2011","journal-title":"Neurology"},{"key":"e_1_2_12_143_1","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/9455237","article-title":"Efgartigimod as Rescue Medication in a Patient With Therapy\u2010Refractory Myasthenic Crisis","volume":"2024","author":"Alhaj Omar O.","year":"2024","journal-title":"Case Reports in Neurological Medicine"},{"key":"e_1_2_12_144_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a Promising Add\u2010On Therapy for Myasthenic Crisis: A Prospective Case Series","volume":"15","author":"Song J.","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"e_1_2_12_145_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12883-024-03804-y","article-title":"Efgartigimod Combined With Steroids as a Fast\u2010Acting Therapy for Myasthenic Crisis: A Case Report","volume":"24","author":"Ohara H.","year":"2024","journal-title":"BMC Neurology"},{"key":"e_1_2_12_146_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a Fast\u2010Acting Add\u2010On Therapy in Manifest and Impending Myasthenic Crisis: A Single\u2010Center Case Series","volume":"395","author":"Hong Y.","year":"2024","journal-title":"Journal of Neuroimmunology"},{"issue":"6","key":"e_1_2_12_147_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2169\/internalmedicine.3726-24","article-title":"Efgartigimod Successfully Ameliorated Acute Exacerbation of Myasthenia Gravis With Anti\u2010Muscle\u2010Specific Kinase Antibodies","volume":"64","author":"Tanaka K.","year":"2025","journal-title":"Internal Medicine"},{"key":"e_1_2_12_148_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1321058","article-title":"Case Report: Recovery From Refractory Myasthenic Crisis to Minimal Symptom Expression After Add\u2010On Treatment With Efgartigimod","volume":"15","author":"Watanabe K.","year":"2024","journal-title":"Frontiers in Neurology"},{"key":"e_1_2_12_149_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241254895","article-title":"Rescue Treatment With Add\u2010On Efgartigimod in a Patient With Impending Myasthenic Crisis: A Case Report","volume":"17","author":"Zhang Z.","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"e_1_2_12_150_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241307687","article-title":"First Line Treatment With Subcutaneous Efgartigimod in Impending Myasthenic Crisis: A Case Report","volume":"17","author":"Kwiedor I.","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"e_1_2_12_151_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1524200","article-title":"Case Report: Successful Perioperative Intervention With Efgartigimod in a Patient in Myasthenic Crisis","volume":"16","author":"Shelly S.","year":"2025","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_152_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1486659","article-title":"Efgartigimod Treatment in Patients With Anti\u2010MuSK\u2010Positive Myasthenia Gravis in Exacerbation","volume":"15","author":"Shi F.","year":"2024","journal-title":"Frontiers in Neurology"},{"issue":"1","key":"e_1_2_12_153_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79918-7","article-title":"Efgartigimod Versus Intravenous Immunoglobulin in the Treatment of Patients With Impending Myasthenic Crisis","volume":"14","author":"Ma J.","year":"2024","journal-title":"Scientific Reports"},{"issue":"2","key":"e_1_2_12_154_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The Use of Eculizumab in Ventilator\u2010Dependent Myasthenia Gravis Patients","volume":"64","author":"Usman U.","year":"2021","journal-title":"Muscle & Nerve"},{"issue":"9","key":"e_1_2_12_155_1","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement Inhibition Initiated Recovery of a Severe Myasthenic Crisis With COVID\u201019","volume":"268","author":"Hofstadt\u2010van Oy U.","year":"2021","journal-title":"Journal of Neurology"},{"issue":"4","key":"e_1_2_12_156_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70596","article-title":"Complement Inhibition Therapy in Myasthenic Crisis\u2014A Multicentre Retrospective Analysis of 17 Cases From Germany","volume":"33","author":"Gerischer L.","year":"2026","journal-title":"European Journal of Neurology"},{"issue":"2","key":"e_1_2_12_157_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s12028-025-02272-7","article-title":"Eculizumab as Treatment in Refractory Impeding and Myasthenic Crisis: A Case Series","volume":"43","author":"Erra C.","year":"2025","journal-title":"Neurocritical Care"},{"key":"e_1_2_12_158_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241261602","article-title":"The Safety and Efficacy Profile of Eculizumab in Myasthenic Crisis: A Prospective Small Case Series","volume":"17","author":"Song J.","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"11","key":"e_1_2_12_159_1","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","article-title":"Eculizumab as a Fast\u2010Acting Rescue Therapy in a Refractory Myasthenic Crisis: A Case Report","volume":"269","author":"Strano C. M. M.","year":"2022","journal-title":"Journal of Neurology"},{"issue":"12","key":"e_1_2_12_160_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.5692\/clinicalneurol.cn-001483","article-title":"Eclizumab in the Treatment of Myasthenia Gravis Crisis Complicating Invasive Thymoma: A Case Study of Efficacy","volume":"60","author":"Yoshizumi K.","year":"2020","journal-title":"Rinsh\u014d Shinkeigaku"},{"issue":"4","key":"e_1_2_12_161_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5692\/clinicalneurol.cn-001682","article-title":"The Efficacy of Eculizumab Against Post\u2010Thymectomy Exacerbations in Thymoma Associated Myasthenia Gravis (MG)","volume":"62","author":"Takeuchi E.","year":"2022","journal-title":"Rinsh\u014d Shinkeigaku"},{"issue":"10","key":"e_1_2_12_162_1","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting Eculizumab as Rescue Therapy in Refractory Myasthenic Crisis","volume":"44","author":"Vinciguerra C.","year":"2023","journal-title":"Neurological Sciences"},{"issue":"2","key":"e_1_2_12_163_1","first-page":"E13","article-title":"Eculizumab in Refractory Myasthenic Crisis","volume":"58","author":"Yeo C. J. J.","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"4","key":"e_1_2_12_164_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/25785826.2025.2500698","article-title":"Rapid Response of Eculizumab: A Rescue Therapy for Ventilator\u2010Dependent Refractory Myasthenic Crisis","volume":"48","author":"Takenobu Y.","year":"2025","journal-title":"Immunological Medicine"},{"issue":"7","key":"e_1_2_12_165_1","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1007\/s10072-025-08128-4","article-title":"Prominent and Fast Response to Eculizumab in Myasthenic Crisis: The Potential as Rescue Therapy in Refractory Myasthenia Gravis","volume":"46","author":"Messina C.","year":"2025","journal-title":"Neurological Sciences"},{"issue":"3","key":"e_1_2_12_166_1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s12028-025-02237-w","article-title":"Eculizumab as a Rescue Therapy in Prolonged Myasthenic Crisis in the Intensive Care Unit: A Case Series","volume":"42","author":"Durmus H.","year":"2025","journal-title":"Neurocritical Care"},{"key":"e_1_2_12_167_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.125662","article-title":"Myasthenic Crisis Associated With Invasive Thymoma Successfully Treated With Ravulizumab: A Case Series","volume":"479","author":"Mitsutake A.","year":"2025","journal-title":"Journal of the Neurological Sciences"},{"key":"e_1_2_12_168_1","doi-asserted-by":"crossref","DOI":"10.1155\/crnm\/1381459","article-title":"Ravulizumab in the Management of Refractory Myasthenic Crisis: Clinical and Ventilatory Evidence of Early Recovery\u2014A Case Report","volume":"2025","author":"Manlio S.","year":"2025","journal-title":"Case Reports in Neurological Medicine"},{"issue":"5","key":"e_1_2_12_169_1","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1007\/s00415-024-12234-2","article-title":"Ravulizumab in Myasthenic Crisis: The First Case Report","volume":"271","author":"Konen F. F.","year":"2024","journal-title":"Journal of Neurology"},{"issue":"8","key":"e_1_2_12_170_1","first-page":"921","article-title":"[Myasthenia Gravis Treated With Zilucoplan Prior to Extended Transsternal Thymectomy for the Prevention of Myasthenic Crisis: A Case Report]. Article in Japanese","volume":"77","author":"Yamanaka N.","year":"2025","journal-title":"Brain and Nerve"},{"issue":"3","key":"e_1_2_12_171_1","article-title":"Zilucoplan for Successful Early Weaning From Mechanical Ventilation and Avoiding Tracheostomy in an 85\u2010Year\u2010Old Woman Experiencing Myasthenic Crisis: A Case Report","volume":"17","author":"Ito S.","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_12_172_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251319656","article-title":"Patterns and Predictors of Therapeutic Response to Efgartigimod in Acetylcholine Receptor\u2010Antibody Generalized Myasthenia Gravis Subtypes","volume":"18","author":"Jin L.","year":"2025","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"4","key":"e_1_2_12_173_1","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70391","article-title":"Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real\u2010World Cohort of 77 Patients","volume":"31","author":"Hao S.","year":"2025","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"3","key":"e_1_2_12_174_1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real\u2010World Experience With FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition From Intravenous to Subcutaneous Formulation","volume":"14","author":"Yoshikawa M.","year":"2025","journal-title":"Neurology and Therapy"},{"issue":"12","key":"e_1_2_12_175_1","article-title":"Exacerbation of Thymoma\u2010Associated Myasthenia Gravis Following Efgartigimod Treatment Related to Anti\u2010Acetylcholine Receptor Antibody Overshoot: A Report of Two Cases","volume":"15","author":"Kawama K.","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_12_176_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241309431","article-title":"Eculizumab in Thymoma\u2010Associated Myasthenia Gravis: A Real\u2010World Cohort Study","volume":"17","author":"Jin L.","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"8","key":"e_1_2_12_177_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.26.8.729","article-title":"Long\u2010Term Administration of Corticosteroids in Myasthenia Gravis","volume":"26","author":"Mann J. D.","year":"1976","journal-title":"Neurology"},{"issue":"12","key":"e_1_2_12_178_1","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1007\/s10072-024-07577-7","article-title":"Therapeutic Challenges and Unmet Needs in the Management of Myasthenia Gravis: An Italian Expert Opinion","volume":"45","author":"Mantegazza R.","year":"2024","journal-title":"Neurological Sciences"},{"issue":"3","key":"e_1_2_12_179_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/mus.28328","article-title":"International Consensus Guidance for the Management of Glucocorticoid Related Complications in Neuromuscular Disease","volume":"71","author":"Bacher C.","year":"2025","journal-title":"Muscle & Nerve"},{"issue":"3","key":"e_1_2_12_180_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil for Myasthenia Gravis (PROMISE\u2010MG): A Prospective Cohort Study","volume":"23","author":"Narayanaswami P.","year":"2024","journal-title":"Lancet Neurology"},{"issue":"5","key":"e_1_2_12_181_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/mus.70177","article-title":"The Duke MG Patient Registry III: Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review","volume":"73","author":"Sanders D. B.","year":"2026","journal-title":"Muscle & Nerve"},{"issue":"4","key":"e_1_2_12_182_1","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-12958-9","article-title":"Safety and Efficacy of Chronic Weekly Rozanolixizumab in Generalized Myasthenia Gravis: The Randomized Open\u2010Label Extension MG0004 Study","volume":"272","author":"Bril V.","year":"2025","journal-title":"Journal of Neurology"},{"issue":"23","key":"e_1_2_12_183_1","first-page":"S37","article-title":"Long\u2010Term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study","volume":"99","author":"Howard J.","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"e_1_2_12_184_1","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1212\/WNL.0000000000211115","article-title":"Long\u2010Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity\u2010MG3 Open\u2010Label Extension Phase Results (P7\u201011.022)","volume":"104","author":"Antozzi C.","year":"2025","journal-title":"Neurology"},{"issue":"2","key":"e_1_2_12_185_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/22143602241305511","article-title":"Rozanolixizumab in Generalized Myasthenia Gravis: Pooled Analysis of the Phase 3 MycarinG Study and Two Open\u2010Label Extensions","volume":"12","author":"Bril V.","year":"2025","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"1","key":"e_1_2_12_186_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long\u2010Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis","volume":"60","author":"Muppidi S.","year":"2019","journal-title":"Muscle & Nerve"},{"issue":"7","key":"e_1_2_12_187_1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long\u2010Term Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis: Responder Analyses","volume":"8","author":"Howard J. F.","year":"2021","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"8","key":"e_1_2_12_188_1","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long\u2010Term Efficacy and Safety of Ravulizumab in Adults With Anti\u2010Acetylcholine Receptor Antibody\u2010Positive Generalized Myasthenia Gravis: Results From the Phase 3 CHAMPION MG Open\u2010Label Extension","volume":"270","author":"Meisel A.","year":"2023","journal-title":"Journal of Neurology"},{"issue":"4","key":"e_1_2_12_189_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70158","article-title":"Long\u2010Term Efficacy and Safety of Ravulizumab in Adults With Anti\u2010Acetylcholine Receptor Antibody\u2010Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open\u2010Label Extension","volume":"32","author":"Vu T. H.","year":"2025","journal-title":"European Journal of Neurology"},{"issue":"8","key":"e_1_2_12_190_1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s11136-019-02204-x","article-title":"Correction to: Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis","volume":"28","author":"Andersen H.","year":"2019","journal-title":"Quality of Life Research"},{"key":"e_1_2_12_191_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241243186","article-title":"Long\u2010Term Safety and Efficacy of Zilucoplan in Patients With Generalized Myasthenia Gravis: Interim Analysis of the RAISE\u2010XT Open\u2010Label Extension Study","volume":"17","author":"Howard J. F.","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"5","key":"e_1_2_12_192_1","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s00415-024-12209-3","article-title":"Improvement of Fatigue in Generalised Myasthenia Gravis With Zilucoplan","volume":"271","author":"Weiss M. D.","year":"2024","journal-title":"Journal of Neurology"},{"key":"e_1_2_12_193_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG Regulation Through FcRn Blocking: A Novel Mechanism for the Treatment of Myasthenia Gravis","volume":"430","author":"Wolfe G. I.","year":"2021","journal-title":"Journal of the Neurological Sciences"},{"issue":"20","key":"e_1_2_12_194_1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti\u2010MuSK Autoantibodies Block Binding of Collagen Q to MuSK","volume":"77","author":"Kawakami Y.","year":"2011","journal-title":"Neurology"},{"issue":"51","key":"e_1_2_12_195_1","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 Autoantibodies Cause Myasthenia Gravis by Inhibiting Binding Between MuSK and Lrp4","volume":"110","author":"Huijbers M. G.","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"e_1_2_12_196_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical Fluctuations in MuSK Myasthenia Gravis Are Related to Antigen\u2010Specific IgG4 Instead of IgG1","volume":"195","author":"Niks E. H.","year":"2008","journal-title":"Journal of Neuroimmunology"},{"issue":"11","key":"e_1_2_12_197_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 With MuSK but Both IgG4 and IgG1\u20103 Can Disperse Preformed Agrin\u2010Independent AChR Clusters","volume":"8","author":"Koneczny I.","year":"2013","journal-title":"PLoS One"},{"key":"e_1_2_12_198_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 Autoantibodies Against Muscle\u2010Specific Kinase Undergo Fab\u2010Arm Exchange in Myasthenia Gravis Patients","volume":"77","author":"Koneczny I.","year":"2017","journal-title":"Journal of Autoimmunity"},{"issue":"5","key":"e_1_2_12_199_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody Effector Mechanisms in Myasthenia Gravis\u2014Pathogenesis at the Neuromuscular Junction","volume":"43","author":"Gomez A. M.","year":"2010","journal-title":"Autoimmunity"},{"issue":"12","key":"e_1_2_12_200_1","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of Innovative Therapies in Myasthenia Gravis: A Systematic Review, Meta\u2010Analysis and Network Meta\u2010Analysis","volume":"30","author":"Sacca F.","year":"2023","journal-title":"European Journal of Neurology"},{"issue":"6","key":"e_1_2_12_201_1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","article-title":"Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto\u2010Antibody\u2010Positive (AChR\u2010Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison","volume":"41","author":"Steen C.","year":"2024","journal-title":"Advances in Therapy"},{"issue":"4","key":"e_1_2_12_202_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00415-026-13778-1","article-title":"Efficacy and Safety of Complement Inhibitors and FcRn Blockers in Generalized AChR Antibody\u2010Positive Myasthenia Gravis: A Meta\u2010Analysis","volume":"273","author":"Filippakopoulou E.","year":"2026","journal-title":"Journal of Neurology"},{"issue":"2","key":"e_1_2_12_203_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","article-title":"The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta\u2010Analysis","volume":"38","author":"Ma Y.","year":"2024","journal-title":"CNS Drugs"},{"issue":"5","key":"e_1_2_12_204_1","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The Efficacy and Safety of FcRn Inhibitors in Patients With Myasthenia Gravis: A Systematic Review and Meta\u2010Analysis","volume":"271","author":"Li J.","year":"2024","journal-title":"Journal of Neurology"},{"key":"e_1_2_12_205_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1280226","article-title":"Efficacy and Safety of the Innovative Monoclonal Antibodies in Adults With Generalized Myasthenia Gravis: A Bayesian Network Analysis","volume":"14","author":"Chen H.","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"e_1_2_12_206_1","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s12325-026-03543-1","article-title":"Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis","volume":"43","author":"Jacob S.","year":"2026","journal-title":"Advances in Therapy"},{"issue":"4","key":"e_1_2_12_207_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 Complement Inhibition Versus FcRn Modulation in Generalised Myasthenia Gravis","volume":"96","author":"Huntemann N.","year":"2025","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"e_1_2_12_208_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200331","article-title":"Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real\u2010World Study","volume":"12","author":"Stascheit F.","year":"2025","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"5","key":"e_1_2_12_209_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00415-025-13061-9","article-title":"Correction: A Real\u2010Life Experience With Eculizumab and Efgartigimod in Generalized Myasthenia Gravis Patients","volume":"272","author":"Pane C.","year":"2025","journal-title":"Journal of Neurology"},{"issue":"1","key":"e_1_2_12_210_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40120-025-00873-0","article-title":"Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients With Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA","volume":"15","author":"Sacca F.","year":"2026","journal-title":"Neurology and Therapy"},{"issue":"8","key":"e_1_2_12_211_1","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1007\/s00415-022-11140-9","article-title":"Vaccines and Myasthenia Gravis: A Comprehensive Review and Retrospective Study of SARS\u2010CoV\u20102 Vaccination in a Large Cohort of Myasthenic Patients","volume":"269","author":"Sansone G.","year":"2022","journal-title":"Journal of Neurology"},{"key":"e_1_2_12_212_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-026-13268-9","article-title":"Breakthrough Serogroup Y Meningococcal Disease in a Vaccinated Patient With Myasthenia Gravis Receiving Ravulizumab: A Case Report","volume":"26","author":"Strugar S. S.","year":"2026","journal-title":"BMC Infectious Diseases"},{"key":"e_1_2_12_213_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/DHPS.S257009","article-title":"Risk Analysis of Eculizumab\u2010Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database","volume":"12","author":"Matsumura Y.","year":"2020","journal-title":"Drug, Healthcare and Patient Safety"},{"key":"e_1_2_12_214_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123628","article-title":"First Analysis of the Myasthenia Gravis SPOTLIGHT Registry: Outcomes With Eculizumab and Ravulizumab","volume":"476","author":"Howard J. F.","year":"2025","journal-title":"Journal of the Neurological Sciences"},{"issue":"5","key":"e_1_2_12_215_1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/acn3.52051","article-title":"Real\u2010World Experience With Eculizumab and Switching to Ravulizumab for Generalized Myasthenia Gravis","volume":"11","author":"Tokuyasu D.","year":"2024","journal-title":"Annals of Clinical Translational Neurology"},{"key":"e_1_2_12_216_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1378080","article-title":"Ravulizumab Use for Acetylcholine Receptor\u2013Positive Generalized Myasthenia Gravis in Clinical Practice","volume":"15","author":"Katyal N.","year":"2024","journal-title":"Frontiers in Neurology"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.70418","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:06:29Z","timestamp":1791871589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.70418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":215,"alternative-id":["10.1002\/mus.70418"],"URL":"https:\/\/doi.org\/10.1002\/mus.70418","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"2026-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"mus.70418"}}